ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+59.32%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$180M
AUM Growth
+$180M
(+7.2%)
Cap. Flow
-$77.8M
Cap. Flow
% of AUM
-43.26%
Top 10 Holdings %
Top 10 Hldgs %
65.55%
Holding
34
New
12
Increased
4
Reduced
5
Closed
12
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$15.3M |
| 2 |
CG Oncology
CGON
|
$14.1M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$11.9M |
| 4 |
MindMed
MNMD
|
$9.41M |
| 5 |
Kura Oncology
KURA
|
$7.79M |
Top Sells
| 1 |
argenx
ARGX
|
$13.3M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$11.6M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$10.1M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$8.98M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
$8.66M |
Sector Composition
| 1 | Healthcare | 98.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-489,938
| Closed | -$11.6M |
|
|
ALPN
27
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-357,271
| Closed | -$6.81M |
|
|
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-141,348
| Closed | -$10.1M |
|
|
29
MoonLake Immunotherapeutics
MLTX
$3.78B
| – | – |
-143,479
| Closed | -$8.66M |
|
30
Compass Therapeutics
CMPX
$466M
| – | – |
-834,630
| Closed | -$1.3M |
|
31
Axsome Therapeutics
AXSM
$6.09B
| – | – |
-100,862
| Closed | -$8.03M |
|
|
32
argenx
ARGX
$44.2B
| – | – |
-35,000
| Closed | -$13.3M |
|
|
33
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-150,000
| Closed | -$8.98M |
|
34
Amylyx Pharmaceuticals
AMLX
$877M
| – | – |
-275,773
| Closed | -$4.06M |
|